Meningitis Vax Tied to Bell’s Palsy Risk

By Dr. Mercola The U.S. Centers for Disease Control and Prevention (CDC) recommends meningococcal conjugate vaccines (brand names Menactra and Menveo) for all 11- to 12-year-olds along with a booster dose at 16.1 Menactra and Menveo vaccines (MCV4) contain four strains of meningococcal (A, C, W-35, Y) and are intended to help prevent invasive meningococcal disease, which is a bacterial infection caused by Neisseria meningitidis, or meningococcus, when the bacterium enters the blood stream. Meningococcal organisms are naturally present in the throat and nasal passages of humans and the majority of children develop antibodies to the bacteria without having any symptoms. There is a very low incidence of meningococcal disease in the U.S. but, rarely, individuals who are genetically or biologically susceptible to developing invasive meningococcal disease are at risk for severe injury and death, including loss of limbs. Symptoms may start out similar to influenza and can progress to nausea,
http://articles.mercola.com/sites/articles/archive/2017/01/10/meningococcal-vaccination-linked-to-bells-palsy.aspx